Newport, United Kingdom and Amsterdam, the Netherlands, July 21, 2021 - Nanopharm Ltd., an Aptar Pharma company, and Leyden Labs today announced that they have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs' portfolio and Nanopharm's expertise in the development of nasally delivered drug products.

Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies.

"Leyden Labs is taking a really exciting approach to finding solutions for the broad-spectrum prophylactic protection against respiratory viruses," commented Jag Shur, CEO of Nanopharm.

Guillaume Brouet, Vice-President Analytical, Regulatory and Scientific Affairs at Aptar Pharma added, "We are pleased to support Leyden Labs in this important development."

Koenraad Wiedhaup, CEO of Leyden Labs, stated, "Nanopharm's team has the world-leading expertise needed to understand and develop safe, effective formulations targeting respiratory viruses."

All formulation development will be performed at Nanopharm's facility in Newport, United Kingdom.

About Nanopharm
Nanopharm is an Aptar Pharma company and is a leading provider of tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products. For more information, visit www.nanopharm.co.uk, or for more information on AptarGroup, Inc., please visit www.aptar.com.

About Leyden Laboratories B.V.
To learn more, visit www.leydenlabs.com.

Media contacts:
Nanopharm: Gemma Budd, Director of Business Development, +44 7342 059576, G.Budd@nanopharm.co.uk
Leyden Labs: Elizabeth Miller, M.D., LifeSci Communications, media@leydenlabs.com